Tadalafil Tablet
Product Images NDC 71205-734

Product Visual Gallery

This gallery contains 12 technical images submitted to the FDA as part of the official labeling for Tadalafil (NDC 71205-734). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Proficient Rx Lp, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

71205-735-30 (Tadalafil 10mg)

Label for Tadalafil 10 mg oral tablets by Proficient Rx LP. The package contains 30 light yellow to yellow oval-shaped, film-coated tablets, each debossed with 'T10' on one side. Marketed by Ajanta Pharma USA Inc., the label includes storage instructions and manufacturer information, noting the product is made in India.*

FDA Label Image

71205-736-90 (Tadalafil 20mg)

Packaging label for Tadalafil 20 mg tablets by Proficient Rx LP. The label states 90 tablets per container, each containing 20 mg of Tadalafil. Tablets are described as light yellow to yellow, oval-shaped, and film-coated with "T20" debossed on one side. The label includes storage instructions and notes tablets should not be split.*

FDA Label Image

71205-734-90 (Tadalafil 5mg)

Label for Tadalafil 5 mg oral tablets by Proficient Rx LP, containing 90 film-coated tablets. The label includes active ingredient details (Tadalafil USP 5 mg), a description of the tablets as light yellow to yellow, oval-shaped, film-coated with 'T5' debossed on one side. Marketed by Ajanta Pharma USA Inc., made in India, and storage instructions at 20°-25°C (68°-77°F) are noted.*

FDA Label Image

Figure8 (Tadalafil Fig8)

A line graph showing change from baseline in IPSS Total Score over 12 weeks comparing Tadalafil 5 mg tablet and placebo. The y-axis represents change from baseline, and the x-axis shows treatment duration in weeks. Tadalafil shows a greater decrease in score over time compared to placebo, with statistical significance at 12 weeks (p<0.01).*

FDA Label Image

Figure1 (Tadalafil Figure1)

A set of four line graphs showing blood pressure changes over time in hours for tadalafil versus placebo. The graphs display standing systolic, standing diastolic, supine systolic, and supine diastolic blood pressure, with differences in mmHg on the y-axis and time on the x-axis, including error bars for variability.*

FDA Label Image

Figure2 (Tadalafil Figure2)

A two-panel line graph showing changes in standing and supine systolic blood pressure (mmHg) over 24 hours post-dose. The top panel displays standing systolic blood pressure changes, while the bottom panel shows supine systolic blood pressure changes. Data compare Tadalafil 20 mg combined with doxazosin 8 mg versus placebo combined with doxazosin 8 mg over time.*

FDA Label Image

Figure3 (Tadalafil Figure3)

Line graph showing the effect on systolic blood pressure (mm Hg) over 12 hours after administration of tadalafil or placebo, both combined with doxazosin. Multiple groups are plotted, including 20 mg tadalafil and placebo at morning and evening dosing times, illustrating blood pressure changes relative to baseline.*

FDA Label Image

Figure4 (Tadalafil Figure4)

A line graph depicting plasma tadalafil concentration (μg/L) over time (hours) for three dosing regimens: a single 20-mg tadalafil dose, a single 5-mg tadalafil dose, and once-daily 5-mg tadalafil following 5 consecutive days of administration. The graph shows concentration decline over 120 hours with error bars for variability.*

FDA Label Image

Figure5 (Tadalafil Figure5)

A line graph comparing the change from baseline in IPSS Total Score over a 12-week treatment period between Tadalafil 5 mg and placebo. The x-axis represents treatment duration in weeks, and the y-axis shows the change in score, with Tadalafil 5 mg showing a greater decrease than placebo. Statistical significance is indicated with p<0.01.*

FDA Label Image

Figure6 (Tadalafil Figure6)

A line graph depicting the change from baseline in IPSS total score over 12 weeks of treatment, comparing Tadalafil 5 mg and placebo. The x-axis represents the duration of treatment in weeks, and the y-axis shows the change from baseline in the IPSS total score, with a noted statistical significance marker for p<0.01.*

FDA Label Image

Figure7 (Tadalafil Figure7)

A line graph titled "Weeks of Therapy" depicting the least squares mean change from baseline over 26 weeks for two treatments: Tadalafil/Finasteride and Placebo/Finasteride. The graph shows data points at 0, 4, 12, and 26 weeks, with the Tadalafil/Finasteride group showing greater reduction from baseline compared to placebo. Statistical significance is indicated at certain points (p<0.001 and p<0.05).*

FDA Label Image

Structure (Tadalafil Structure)

Chemical structure diagram of tadalafil, a prescription drug active ingredient. The diagram shows atoms and bonds representing the molecular composition of tadalafil.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.